Omeros
Manufacturing · Washington, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
201 Elliott Ave W, Seattle, Washington, ...Phone Number
(206) 676-5000Website
www.omeros.comRevenue
$68.2 MillionStock Symbol
OMERIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
3
1
1
1
1
About Omeros
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded in 1994.Explore more
Omeros Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Omeros your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Omeros has new funding data
Check out if Omeros is spiking on competitors!
Product Launch: Get notified when Omeros launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Omeros had a recent Job posting/layoffs
Check if Omeros has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Omeros recently announced quarterly report
Omeros, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Omeros
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Omeros
Compare insights from companies similar to Omeros, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Omeros is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Omeros is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Omeros.
Omeros financials insights
Gather financial insights about Omeros, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$84M
2016
Multiple Rounds
$215M
2017
Stock Offering
$63.6M
2018
Debt
$210M
2019
Stock Offering
$57.5M
2024
Debt
$92.1M
2025
Other Financing Round
$4M
Omeros Tech Stack
A closer look at the technologies used by Omeros
See more technologies
Most Recent Scoops
Earnings
Omeros has reported that the US Centers for Medicare & Medicaid Services assigned a permanent J-code for YARTEMLEA in April, effective July 1, which is expected to simplify billing and reimbursement across payers, reduce administrative burden, and improve reimbursement predictability.
Accounting, Billing & Invoice, Finance
Earnings
Omeros has reported that during Q1 2026, it repurchased and retired approximately 360,000 shares of common stock at an average price of $11.70 per share for a total of $4.2 million, and may continue to repurchase shares subject to market conditions and other considerations.
Stake & Stock Ownership, Finance
Earnings
Omeros has reported that by March 31, 2026, 60% of the top 10, 40% of the top 20, 38% of the top 40, and approximately 30% of the top 80 US transplant centers had received P&T committee approval for YARTEMLEA, reflecting adoption ahead of the typical 6 to 9-month approval timeline.
Clinical Operations
Project
Omeros has announced that data from its targeted complement activating therapy (TCAT) platform, a novel class of recombinant antibodies designed to kill multidrug-resistant pathogens regardless of resistance profile, were featured in a podium presentation at the annual congress of the European Society of Clinical Microbiology and Infectious Diseases, and that the seminal manuscript describing the TCAT technology has been accepted for publication in Science Translational Medicine.
Medical Research, Pharmaceuticals
Earnings
Earnings, Finance
Omeros News & Media
Omeros Corp (OMER) Q4 2025 Earnings Call Highlights: A Turnaround with Strategic Deals and FDA ...
Omeros Corp (OMER) reports a significant net income turnaround, bolstered by a major transaction with Novo Nordisk and the FDA approval of YARTEMLEA.Omeros Q4 Earnings Call Highlights
Omeros (NASDAQ:OMER) executives highlighted two “major successes” in the fourth quarter of 2025 that they said marked a turning point for the company: closing a $240 million upfront asset sale and license deal with Novo Nordisk for the phase III-ready complement asset zaltenibart, and receiving FDAWhy Omeros Stock Skyrocketed Today
The company is on the brink of commercializing a unique medication.Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz
Omeros Corporation (NASDAQ:OMER) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. Latest reports show that Omeros Corporation (NASDAQ:OMER) has closed a deal worth around $2.1 billion with drug giant Novo Nordisk for the zaltenibart, a phase 2 asset of the former, in development for rare blood and kidney disorders. Omeros […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Omeros
Sign Up For FreeTo access detailed company insights
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded in 1994.... Read More
